Prism Medical (PM) Earns Media Sentiment Score of 1.86

News stories about Prism Medical (CVE:PM) have been trending somewhat positive on Saturday, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prism Medical earned a daily sentiment score of 1.86 on their scale. InfoTrie also assigned media coverage about the company an news buzz score of 4 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Prism Medical stock traded up C$0.34 during trading hours on Friday, hitting C$80.44. The company had a trading volume of 5,784,382 shares, compared to its average volume of 6,260,029. Prism Medical has a fifty-two week low of C$79.71 and a fifty-two week high of C$123.55.

WARNING: “Prism Medical (PM) Earns Media Sentiment Score of 1.86” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

Prism Medical Company Profile

Prism Medical Ltd. is a provider of durable medical equipment and services used to the mobility challenged individuals. The Company’s business units include Prism Medical Canada and Prism Medical United States. The Company’s products are marketed under the brand names of Prism Medical, Ergosafe, Waverley Glen and Nightingale in the home care, acute care and long-term care markets in the United States and Canada.

See Also: S&P 500 Index

Receive News & Ratings for Prism Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prism Medical and related companies with's FREE daily email newsletter.

Leave a Reply